PhRMA

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from PhRMA, Medical and health, 670 Maine Avenue SW Ste. 1000, Washington D.C., DC.

We represent America’s innovative biopharmaceutical research & biotechnology companies, advocating for policies that support the discovery of new medicines and ensure broad patient access to safe, effective treatments.

09/03/2025

Big, tax-exempt hospitals are abusing the little known federal 340B program to charge steep markups on medicines, increasing drug costs for Americans.

That’s why we’re launching “Meet Mark” — a new ad campaign that sheds light on how the 340B hospital markup program is driving up costs for patients, taxpayers and employers.

It’s time for Congress to fix 340B: https://phrma.org/blog/new-meet-mark-ad-exposes-how-the-340b-hospital-markup-program-drives-up-costs-for-everyone

08/28/2025

Scientific breakthroughs don’t happen overnight, or on the first try. Every new medicine and cure is backed by major investments and years of research and resilience.

That’s why it’s critical for public policy to continue fostering an environment where innovators are supported through the ups and downs of drug discovery. Hear more from Nicole Harriott at Neurocrine about the importance of protecting incentives for R&D.

08/22/2025

August marks National Immunization Awareness Month, a time to recognize the vital role vaccines play in safeguarding your health, family and our future.

PhRMA’s Chief Medical Officer, Dr. Mike Ybarra, breaks down 5 key things to know about vaccines—from how they work to the value of access and innovation.

https://phrma.org/blog/recognizing-the-importance-of-vaccination-for-american-health-and-security

08/19/2025

Patients with chronic diseases are battling PBMs and commercial insurers just to get the medicines their doctors prescribe.

A new IQVIA study reveals the scope of the problem:
📊 In 4 of 5 chronic disease areas, more than 90% of patients faced initial denials.
⏳ Many endured weeks-long delays and multiple rejections.
🚫 Up to 67% never got treatment in the first year — and many never started any new medicine at all.

These aren’t just administrative hassles. They’re business decisions by PBMs and insurers that delay or block care.

It’s time for Congress to pass PBM reform.

https://phrma.org/blog/new-study-pbms-and-commercial-insurers-are-quietly-blocking-prescription-access

08/18/2025

In the early 20th century, nearly one in five children died before they turned five, many from infectious disease that are now preventable. Today, vaccines remain one of the most effective tools to keep children and families healthy. It’s critical we maintain high vaccination rates because infectious diseases that were previously eliminated or controlled through vaccines can resurge when vaccination rates decline below a certain threshold.

Learn how vaccine innovation continues to deliver for Americans and our national security, helping them to live longer and healthier lives.

http://innovation.org/vaccines

08/13/2025

The U.S. leads the world in developing, manufacturing and delivering innovative medicines, but other countries aren’t paying their fair share. We must protect the system that delivers breakthroughs and ensure other nations contribute their fair share. Learn how we balance the system while protecting innovation for patients globally.

https://phrma.org/blog/foreign-first-pricing-schemes-don-t-address-why-americans-pay-more

08/11/2025

America’s smart IP policies have incentivized and delivered innovation for patients, but PBMs are creating barriers to accessibility.

A new study shows a troubling pattern: each year the nation’s three largest PBMs have excluded an average of 27% more medicines from many commercial health plans since 2014. This includes an increasing number of generics and biosimilars intended to drive patient savings.

It’s time to increase transparency and hold PBMs accountable.

08/08/2025

A new report shows that as more tax-exempt hospitals exploit the 340B program as a profit center, it increases costs for state and federal taxpayers due to lost Medicaid rebates. In 2024 alone, 340B cost taxpayers and Medicaid an estimated $6.5 billion.

That’s money that could have lowered costs for patients or eased pressure on state budgets. Instead, it’s a hidden tax on patients, taxpayers, and employers—with little benefit for the people the program was meant to serve.

https://phrma.org/blog/the-hidden-cost-of-340b-a-multi-billion-dollar-burden-on-taxpayers-and-medicaid

08/05/2025

The U.S. leads the world in biopharmaceutical innovation—driven by bold investments in R&D and the scientists turning discovery into real-world impact.

To stay competitive and continue breaking new ground in medicine, we must invest in the next generation of talent.

Hear from Nicole Harriott of Neurocrine Biosciences on why nurturing young scientists is critical to America’s leadership in life sciences.

08/04/2025

Every American should have the option to protect themselves and their family with vaccines that are available and accessible. And while vaccines are different by design, they are united in purpose: every vaccine is made to protect Americans.

To kick off National Immunization Awareness Month, PhRMA’s Chief Medical Officer, Mike Ybarra, breaks down how vaccines work, why they matter, and how American innovation helps us stay ahead.

Explore the global impact of American innovation in vaccines at innovation.org/vaccines.

Address

670 Maine Avenue SW Ste. 1000
Washington D.C., DC
20024

Telephone

+12028353400

Website

https://www.PhRMA.org/

Alerts

Be the first to know and let us send you an email when PhRMA posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to PhRMA:

Shortcuts

Want your practice to be the top-listed Clinic in Washington D.C.?